Patent ID: 11964056
Assignee: PURDUE PHARMACEUTICALS L.P.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  B | IPC A  B

Claim 2:
3. The solid oral extended release dosage form of claim 2, wherein the dosage form provides an in-vitro dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) comprising 40% ethanol at 37° C., characterized by the percent amount of active released at 0.5 hours, that deviates no more than about 20% points 0.5 hours from the corresponding in-vitro dissolution rate measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37° C. without ethanol.